Detecting Genetic Risk Factors For Type 1 Diabetes
News Oct 04, 2005
Researchers at the Steno Diabetes Centre in Copenhagen, Denmark, have announced that they are using Applied Biosystems' 7900HT Fast Real-Time PCR System with TaqMan® Gene Expression Assays and Low Density Array cards to identify the genetic risk factors for type 1diabetes.
With the Applied Biosystems' GeneScan® and GeneMapper® software, the researchers are genotyping and analysing the sequences of samples from individuals and families with type 1diabetes.
Prof Flemming Pociot, Head of the Department of Molecular T1D Genetics at the Centre said, “This equipment has served us extremely well, it is well used and it is easy to get support from Applied Biosystems.”
“We are particularly impressed by the TaqMan Low Density Array cards. They give very little variation - which is wonderful - and make data analysis much more straightforward.”
“They are also more sensitive than microarrays for some genes. It is important that we can design arrays with a limited number of genes, for instance, those located in a specific region of the genome, and can run many samples addressing the same expression profiles.”
The data from these studies are being pooled together with data from all over the world as part of the international Type 1 Diabetes Genetics Consortium, which was in part instigated by the Steno Diabetes Centre.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.